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This retrospective quality control study aimed at comparing resolution in patients treated with intravitreal ocriplasmin (IVO)
using two injection techniques, classical injection procedure (unguided) and targeted injection using a surgical microscope with
a 30-gauge 1-inch needle (guided) for the treatment of focal VMT without macular hole. The two groups presented a statistically
significant difference in terms of resolution of VMT within the first month following treatment: 1/7 for the unguided group versus
6/7 for the guided group (𝑝 = 0.0291). The majority of the guided group presented an earlier resolution than the single resolved
case in the unguided group.The results of this preliminary study indicate that the injection of ocriplasmin closer to the site of VMT
results in the resolution in a higher number of cases and that this resolution occurs in a short time interval.
1. Introduction
The scaffold of the vitreous is composed of collagen fibers
(mostly type II) and hyaluronic acid and the posterior
vitreous cortex is a complex structure. In the aging eye, after
age 40, the vitreous gel begins to liquefy involving nearly 50%
by age 80, a process called synchysis. During this time the
posterior vitreous scaffold normally detaches from the retina
with fluid filling the intervening space.
Vitreomacular traction (VMT) occurs when the vitreous
separates from the retina throughout the peripheral fundus
but remains adherent posteriorly, causing an anteroposterior
traction on a small region encompassing the macular and
optic nerve disc. Symptoms include vision impairment and
metamorphopsia, accompanied by photopsia. VMT syn-
drome is associated with a broad spectrum of maculopathies,
including cystoid macular edemas, epiretinal membranes
(ERM), and macular holes (MH) [1–3].
Current treatment options include intravitreal injec-
tions with pharmacological agents that induce an enzymatic
vitreolysis to induce complete VMT resolution. One of these
pharmacological agents, ocriplasmin (Jetrea, Thrombogen-
ics, Leuven, Belgium), was approved in October 2012 by
the United States Food and Drug Administration for the
treatment of symptomatic VMT [4]. It was reported to have
a superior efficacy for VMT resolution compared to placebo
injection in phase III randomized, controlled trials [4].
Although intravitreal injections are considered a corner-
stone of retinal care and one of the most commonly per-
formed procedures across all specialties, the technique is still
undergoing evolution. Currently, the principle debates con-
cerning intravitreal injections concern the gauge of the needle
and the angle/path of scleral penetration [5, 6]. An important
aspect of this procedure that has not been adequately evalu-
ated concerns the site in which the agents are released.
For over twenty years, forensic pathologists have known
the importance of extracting all of the vitreous humor for
analysis given that it presents variations in solute concentra-
tion if sampled in the center or in periphery [7]. Filas et al.
reported that in vivo vitreolytic agents cause the vitreous to
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Figure 1: (a) The unguided injection techniques as suggested by the manufacturer. (b) Additional equipment (30-gauge 1-inch long needle,
surgical microscope, and direct contact lens) used for the guided injections. (c) Detail of the injection site release which was not less than
3mm.
contract and to lose its capacity to bind water with digestion.
They also found that proteins spanning the vitreoretinal inter-
face are not affected by hyaluronidase and concluded that
these combined effects could exacerbate traction. This could
explain why transient vision loss is observed after intravitreal
injections [8]. de Smet et al. also recommended injecting the
enzyme close to the VMT in order to improve effectiveness
[9]. Based on these results we decided tomodify our injection
procedure by performing a standard intravitreal injection
procedure with a surgical microscope equipped with an OCT
scanner in an operating room setting and a longer needle in
order to release the pharmaceutical agent closer to the VMT.
This retrospective quality control study aimed at compar-
ing resolution in patients treated with intravitreal ocriplas-
min (IVO) using two different injecting techniques, standard
injection procedure (unguided) and proximal injection using
a surgical microscope and a 30-gauge 1-inch needle (guided)
for the treatment of focal VMT without macular hole (MH).
2. Patients and Methods
This quality assessment [10] nonrandomized retrospective
consecutive case series study adhered to the tenets of the
Declaration of Helsinki and received approval from an insti-
tution review board. The first fourteen consecutive patients
with VMT without MH treated with intravitreal ocriplasmin
with two different injecting techniques between June 2014
and September 2015 at the Ophthalmic Clinic of University
Chieti-Pescara (Italy) were enrolled. Informed consent was
obtained from all patients prior to their enrollment. Patients
underwent complete ophthalmic evaluation, including Log-
MAR visual acuity (VA) testing, and spectral-domain optical
coherence tomography (SD-OCT) at baseline and follow-up
controls.
2.1. Outcome Measures. The primary outcome measure was
VMT resolution. Secondary outcomes were time to resolu-
tion, visual acuity, and central macular thickness measured
with OCT.
Following injection, patients were visited one day after
injection, and at five-day intervals for 30 days. They were
also instructed to present within 24 hours if they noted a
modification in their vision. During the first follow-up visit
the treated eye was uncovered, VA was assessed, and an
OCT was acquired. Visual acuity was assessed with the Early
Treatment Diabetic Retinopathy Study (ETDRS) chart and
standardized measurement criteria [11].
SD-OCT images were acquired through a dilated pupil
using an RTVUE XR Avanti (version 2015.100.0.35, Optovue
Inc., Fremont, CA) andRTVue-100 (Optovue version 5.1.0.90,
Fremont, CA). Each evaluation was performed with both
instruments and included a cross-line (10.00mmscan length)
and a 5mm × 5mm retinal map for central macular thickness
(CMT). In addition, RTVUE XR Avanti was used to obtain
enhanced HR line 12mm scan length. Scans were evaluated
by a single experienced ophthalmologist for the presence of
VMT (vitreous adhesion within six mm of the fovea and
elevation of the posterior vitreous cortex), for VMT release
(defined as vitreous release from the macula within a six mm
central retinal field), and for the absence of MH.
2.2. Intravitreal Injection Techniques. The unguided standard
injection procedure (unguided; Figure 1(a)) was performed
according to the manufacturer’s instructions (http://jetrea
.com/wp-content/uploads/JETREAPrescribingInformation
.pdf). Briefly, after the content of the vial reached room
temperature, it was diluted with 0.2mL of 0.9% w/v
sodium chloride (sterile, preservative-free) using an aseptic
technique. Then 0.1mL (equivalent of 0.125mg of ocriplas-
min) was injected in the mid-vitreous area using a 30-gauge
1/2-inch injection needle, inserted 3.5–4.0mm posterior to
the limbus and aimed towards the center of the vitreous
cavity, avoiding the horizontal meridian. The injections were
performed in a sterile operating room but without using a
surgical microscope.
The guided injections (Figures 1(b) and 1(c)) were per-
formed in a similar manner except a 30-gauge 1-inch needle
was used for the injection. Also, a surgical microscope and
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Table 1: Comparison of group characteristics at baseline.
Unguided Guided 𝑝
Age (years) 71.7 ± 10.3 73.1 ± 10.2 0.799∗
Male, 𝑛 (%) 1/7 2/7 1.000∗
Adhesion size, maximum length (𝜇m) 293.27 ± 59.06 326.75 ± 48.02 0.267∗∗
Epiretinal membrane (presence) 2/7 2/7 1.000∗
Phakic lens status, 𝑛 (%) 7/7 6/7 1.000∗
BCVA baseline (logMAR) 0.43 ± 0.26 0.23 ± 0.22 0.121∗∗
Central macular thickness (𝜇m) 368 ± 79 405 ± 89 0.406∗∗
∗Fisher’s Exact Test; ∗∗two-tailed independent sample 𝑡-test.
a contact retinal lens were used to determine the depth
of insertion in order to guarantee that the area of release
corresponded to the site of VMT (not less than 3mm
from the retinal plane). An intraoperative spectral-domain
OCT system integrated into a surgical microscope (Rescan
700 iOCT: Zeiss, Oberkochen, Germany) and evaluation of
the shadow produced by the needle on the retinal surface
were used to determine the distance from the retina during
intravitreal injection.
2.3. Statistical Analysis. All statistical analyses were per-
formed using SPSS 22 (IBM, Armonk, NY) and evaluated at
an alpha level of 0.05. Differences in baseline parameters were
evaluated with Fisher’s Exact Test (qualitative parameters)
and two-tailed independent sample 𝑡-test with correction for
results of Levene’s Test for Equality of Variances (quantita-
tive parameters). The primary outcome was evaluated with
Fisher’s Exact Test. The statistical significance of differences
in the temporal distribution of VMT resolutionwas evaluated
using Kaplan-Meier Survival Curves. Statistically significant
variations of VA and CMT within group between time
points and between groups with single time points were
evaluated using two-tailed pair 𝑡-tests and Mann-Whitney
Tests, respectively.
3. Results
All patients successfully completed follow-up.The two groups
of seven patients did not present statistically significant
differences in terms of age, sex, phakic lens status, and best
corrected visual acuity (Table 1).
The two groups presented a statistically significant dif-
ference in the main outcome measure (resolution of VMT)
within the first month following treatment: 1/7 for the
unguided injection group versus 6/7 for the guided injection
group (𝑝 = 0.0291, Fisher’s Exact Test, Figure 2).TheKaplan-
Meier Survival Curve analysis of the temporal distribution of
VMT resolution indicated a statistically significant difference
between the two groups (𝑝 = 0.004, Figure 3). The majority
of the guided injection group (Figure 4) presented an earlier
resolution than the single resolved case in the unguided
injection group.
Statistically significant intergroup differences for VA and
CMT at the three time points were not observed (Figure 5).
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Figure 2: Distribution of patients presenting resolution of VMT
within the first month following injection.
Time
302520151050
1.0
0.8
0.6
0.4
0.2
0.0
Survival functions
Cu
m
ul
at
iv
e p
ro
po
rt
io
n 
su
rv
iv
in
g 
at
 th
e t
im
e
Unguided injection
Guided injection
Figure 3: Kaplan-Meier Survival Curves of the temporal distribu-
tion of VMT resolution.
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Table 2: Secondary outcomemeasurements: Groupmean of themodifications in visual acuity (logMAR) and central macular thickness (𝜇m)
of individual patients between time points.
Time (days)
0 versus 5 days 0 versus 30 days 5 versus 30 days
VA (logMAR) Mean variation 𝑝 Mean variation 𝑝 Mean variation 𝑝
Unguided injection 0.1 0.111 0.2 0.011 0.1 0.045
Guided injection 0.3 0.003 0.3 0.003 0.3 0.356
CMT (𝜇m) Mean percentage variation 𝑝 Mean percentage variation 𝑝 Mean percentage variation 𝑝
Unguided injection 23 0.251 46 0.045 48 0.293
Guided injection 85 0.004 66 0.005 −20 0.218
𝑝: two-tailed pair 𝑡-test.
Figure 4: Cross-sectional optical coherence tomography images showing patients (from A to F) before (top) and after (bottom) resolution
of vitreomacular traction after intravitreal guided injection of ocriplasmin.
When the intrapatient variation was evaluated, statistically
significant differences in VA were observed between baseline
and five and thirty days for the unguided group and between
baseline and five and thirty days for the guided group
(Table 2).
Statistically significant differences in CMTwere observed
between baseline and thirty days for the unguided group and
between baseline andfive and thirty days for the guided group
(Table 2).
4. Discussion
In this study we investigated the efficacy of ocriplasmin for
VMT when using two different injecting procedures. The
resolution of VMT was observed in 1/7 of patients in the
unguided injection group and in 6/7 of patients in the guided
injection group. In phase III clinical trials, the resolution of
VMT after ocriplasmin injection was reported to be 26.5%
ranging from 41% to 75% with higher percentages in patients
with age less than 65 years, focal adhesions less than or equal
to 1500mm, phakic lens status, and absence of epiretinal
membrane [12–14].
Previous studies reported comparable percentages of
VMT resolution ranging from 42.1% to 66.7% [13, 15].
In our case series, patients did not differ significantly for
baseline characteristics such as age (14/14 were more than
65-year-old), sex distribution (6/7 and 5/7 were female in
the unguided and guided group, resp.), type of VMT (focal
in 14/14 of eyes without ERM and/or MH), and lens status
(pseudophakic in 14/14 patients); thus these aspects could
not account for the differences between the two groups in
resolution rate.
It was demonstrated that injected ocriplasmin has a
high autolytic activity in vitreous and that the presence of
partially liquefied vitreous may reduce the rate of autolysis
prolonging the enzyme activity [9]. During aging the vitreous
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Figure 5: Box plot of visual acuity and centralmacular thickness. Intergroup differences at the three time points are not statistically significant.
physiologically liquefies and separates from the retina; thus it
is possible to hypothesize that, by placing the enzyme deep
inside the vitreous cavity close to the site of VMT, increasing
the probability that it will be in an area that has already under-
gone liquefaction, it will result in a high concentration and a
prolonged action of the enzyme, accounting for the quicker
andhigher percentage of resolution in the ocriplasmin guided
injection group.
The lower percentage of resolution in the ocriplasmin
unguided injection group compared to clinical trials and real
life studies was probably due to the small sample size rather
than a real difference in the study population [13, 14].
The anatomic resolution of VMT was related to a signifi-
cant CMT decrease with a mean percentage variation of 85%
from 0 to 5 days (𝑝 < 0.04) and of 66% from 0 to 30 days (𝑝 <
0.005) in the guided group compared to a mean percentage
variation of 23% from0 to 5 (𝑝 < 0.251) and 46% from 0 to 30
days (𝑝 < 0.045) in the unguided group. The related increase
of VA showed a mean variation of 0.3 logMAR from 0 to 5
and 0 to 30 days (𝑝 < 0.03) in the guided group compared to
a mean variation of 0.1 decimal in the unguided group from
0 to 5 (𝑝 < 0.11) and of 0.2 from 0 to 30 days (𝑝 < 0.011).
Other authors demonstrated a similar improvement of
macular anatomy after ocriplasmin injection. Chatziralli et al.
described a decrease of macular thickness from 389±152 𝜇m
to 263 ± 99 𝜇m for cases with VMT release [15].
Favorable results in terms of visual acuity increase in the
guided group were comparable to VA increase observed in
phase III clinical trial showing at six months: a gain of two
or more lines in 23.7% of patients treated with ocriplasmin
compared to 11.2% of patients in the placebo group (𝑝 <
0.001) [12]. Sharma et al. observed an improvement of two or
more lines at onemonth of follow-up and a gain of three lines
or more for a mean follow-up of 258 days in patients treated
with ocriplasmin for VMT [16].
This study presents several limits. Adverse events were
not evaluated in this study given the low incidencewithwhich
they occur and the small sample size. Transitory vision loss
was not evaluated since treated eyes were patched for the first
24 hours. Another limit of this study was the sample size.
Therefore, prior to drawing conclusive results, a similar study
should be performed in a larger study population using a
multicenter randomized case-control design.
The results of this preliminary study indicate that the
injection of ocriplasmin closer to the site of VMT results
in the resolution in a higher number of cases and that this
resolution occurs in a shorter time interval compared to a
standard injection technique.
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